Regulatory FDA clears Orca’s cell therapy Tregzi for GvHD PharmaphorumOrca becomes a commercial-stage biotech with the approval of Tregzi, a cell therapy to prevent a serious complication of stem cell transplants.HematologyRead full story pharminent July 1, 2026 (Last updated: July 2, 2026) Pharmaphorum Orca becomes a commercial-stage biotech with the approval of Tregzi, a cell therapy to prevent a serious complication of stem cell transplants. Hematology Read full story Post navigation Previous: Lilly’s Jaypirca Wins CHMP Opinion for CLL Across All LinesNext: Sarepta secures early 2027 FDA decision for Duchenne drugs, pushing past confirmatory fail Related Stories Regulatory Scholar Rock’s muscle-targeting SMA therapy Isemblyd lands FDA approval pharminent September 14, 2026 Regulatory Psychedelic therapies ride wave of public favor into FDA hearing pharminent September 14, 2026 Regulatory Bayer’s Hyrnuo set for the NSCLC frontlines on accelerated FDA label expansion pharminent September 10, 2026